Antazoline, tetrahydrozoline (Oculerge)
Antazoline, tetrahydrozoline
Pharmacare limited û woodmead
Registration
- Applicant
- Pharmacare limited û woodmead
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Oculerge EACH 1 ml LIQIUD CONTAINS ANTAZOLINE HYDROCHLORIDE 0,5 mg TETRAHYDROZOLINE HYDROCHLORIDE 0,4 mg | Not listed | 31014431/15.4/0144 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S2: Antazoline
Consolidated Schedules 06 July 2026, line 1590
S2: Tetrahydrozoline
- except when intended for nasal use.
Consolidated Schedules 06 July 2026, line 2717
S1: Tetrahydrozoline
- when intended for nasal use.
Consolidated Schedules 06 July 2026, line 1106
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.